Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA

被引：0
|
作者：
Barnett, Reagan
Lanka, Sree M.
Clemens, Keelia M.
Kiedrowski, Lesli Ann
Babiker, Hani M.
Bryce, Alan Haruo
Meyer, Haley M.
Choi, Yujin
Garje, Rohan
Gao, Xin
Chang, Richard Y.
Jang, Albert
Gulhati, Pat
Bilen, Mehmet Asim
Barata, Pedro C.
机构：
[1] Guardant Hlth Inc, Redwood City, CA USA
[2] Tulane Univ, New Orleans, LA USA
[3] Mayo Clin Florida, Jacksonville, FL USA
[4] Mayo Clin, Phoenix, AZ USA
[5] Mayo Clin, Scottsdale, AZ USA
[6] Emory Univ, Atlanta, GA USA
[7] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA
[8] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[9] Harvard Med Sch, Boston, MA USA
[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA
[11] Tulane Univ, Sch Med, New Orleans, LA USA
[12] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[13] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2561
引用
收藏
页数：1
相关论文
共 50 条
  • [1] High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
    Vareki, Saman Maleki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [2] Landscape of tumor mutational burden-high (TMB-high) and its correlation with immune checkpoint inhibitor biomarkers in gynecologic tumors
    Huang, Richard
    Lin, Douglas
    Danziger, Natalie
    Williams, Erik
    Elvin, Julia
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S196 - S196
  • [3] Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
    Barnett, Reagan M.
    Jang, Albert
    Lanka, Sree
    Fu, Pingfu
    Bucheit, Leslie A.
    Babiker, Hani
    Bryce, Alan
    Meyer, Haley M.
    Choi, Yujin
    Moore, Casey
    Garje, Rohan
    Gao, Xin
    Kim, Dae Won
    Chang, Richard Y.
    Gulhati, Pat
    Ramaker, Ryne
    Bansal, Rani
    Zhang, Tian
    Oliver Sartor, A.
    Armstrong, Andrew J.
    Bilen, Mehmet A.
    Barata, Pedro
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [4] Microsatellite-stable tumors with high tumor mutational burden in association with tumor response to immune checkpoint inhibitor therapy across solid tumors and correlation with specific oncogenic alterations
    Nizamuddin, Imran
    Doukas, Peter
    de Viveiros, Pedro Antonio Hermida
    Mi, Xinlei
    Katam, Neelima
    Chae, Young Kwang
    Behdad, Amir
    Wehbe, Firas Hazem
    Mahalingam, Devalingam
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
    Nassar, Amin H.
    Adib, Elio
    Alaiwi, Sarah Abou
    El Zarif, Talal
    Groha, Stefan
    Akl, Elie W.
    Nuzzo, Pier Vitale
    Mouhieddine, Tarek H.
    Perea-Chamblee, Tomin
    Taraszka, Kodi
    El-Khoury, Habib
    Labban, Muhieddine
    Fong, Christopher
    Arora, Kanika S.
    Labaki, Chris
    Xu, Wenxin
    Sonpavde, Guru
    Haddad, Robert I.
    Mouw, Kent W.
    Giannakis, Marios
    Hodi, F. Stephen
    Zaitlen, Noah
    Schoenfeld, Adam J.
    Schultz, Nikolaus
    Berger, Michael F.
    MacConaill, Laura E.
    Ananda, Guruprasad
    Kwiatkowski, David J.
    Choueiri, Toni K.
    Schrag, Deborah
    Carrot-Zhang, Jian
    Gusev, Alexander
    CANCER CELL, 2022, 40 (10) : 1161 - +
  • [6] RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER
    Lenis, Andrew T.
    Ravichandran, Vignesh
    Hong Truong
    Reisz, Peter
    Nweji, Barbara
    Autio, Karen
    Morris, Michael
    Slovin, Susan
    Vargas, Hebert Alberto
    Laudone, Vincent
    Ehdaie, Behfar
    Reuter, Victor
    Viale, Agnes
    Schultz, Nikolaus
    Gopalan, Anuradha
    Donoghue, Mark
    Stopsack, Konrad
    Solit, David
    Abida, Wassim
    JOURNAL OF UROLOGY, 2021, 206 : E411 - E411
  • [7] CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR GASTRITIS IN PATIENTS WITH CANCER
    Haryal, Aneesha
    Baskaran, Vinitha
    Srivoleti, Padmavathi
    Sack, Jordan S.
    Grover, Shilpa
    GASTROENTEROLOGY, 2022, 162 (07) : S905 - S905
  • [8] Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors
    Yu, James
    Park, Robin
    Miao, Ruoyu
    Imanirad, Iman
    Shahzad, Moazzam
    Laborde, Jose M.
    Knepper, Todd C.
    Walko, Christine M.
    Kim, Richard
    JOURNAL OF IMMUNOTHERAPY, 2024, 47 (09) : 378 - 383
  • [9] INTEGRATING TUMOR MUTATIONAL BURDEN AND TRANSCRIPTOME EXPRESSION INTO PREDICTION OF IMMUNE CHECKPOINT INHIBITOR RESPONSE AND PROGNOSIS OF PATIENTS WITH COLON CANCER
    Liang, L.
    Jiang, W.
    Zheng, Y.
    Liu, T.
    Shen, X.
    Chen, Y.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 73 (02):
  • [10] Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response
    Mai, Nicholas
    Safonov, Anton
    Marra, Antonio
    Chen, Yuan
    Chandarlapaty, Sarat
    Razavi, Pedram
    Plitas, George
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345